Similar articles

• Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska.

  Galil K, Singleton R, Levine OS, Fitzgerald MA, Bulkow L, Getty M, Perkins BA, Parkinson A. Galil K, et al. J Infect Dis. 1999 Jan;179(1):101-6. doi: 10.1086/314569. J Infect Dis. 1999. PMID: 9841828
• The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease.

  Singleton R, Hammitt L, Hennessy T, Bulkow L, DeByle C, Parkinson A, Cottle TE, Peters H, Butler JC. Singleton R, et al. Pediatrics. 2006 Aug;118(2):e421-9. doi: 10.1542/peds.2006-0287. Pediatrics. 2006. PMID: 16882783
• Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): clinical evaluation.

  Ahonkhai VI, Lukacs LJ, Jonas LC, Matthews H, Vella PP, Ellis RW, Staub JM, Dolan KT, Rusk CM, Calandra GB, et al. Ahonkhai VI, et al. Pediatrics. 1990 Apr;85(4 Pt 2):676-81. Pediatrics. 1990. PMID: 2107518 Clinical Trial.
• The challenge of ongoing Haemophilus influenzae type B carriage and transmission in Alaska.

  Lucher LA, Singleton R, Parkinson AJ, Butler JC. Lucher LA, et al. Alaska Med. 1999 Jul-Sep;41(3):61-8. Alaska Med. 1999. PMID: 10540498 Review.
• The continuing role of Haemophilus influenzae type b carriage surveillance as a mechanism for early detection of invasive disease activity.

  Jacups SP. Jacups SP. Hum Vaccin. 2011 Dec;7(12):1254-60. doi: 10.4161/hv.7.12.17979. Epub 2011 Dec 1. Hum Vaccin. 2011. PMID: 22108040 Review.